Trial Profile
A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Rasagiline (Primary)
- Indications Multiple system atrophy; Parkinsonian disorders
- Focus Therapeutic Use
- Sponsors Teva Branded Pharmaceutical Products R&D; Teva Pharmaceutical Industries
- 30 Jun 2012 Planned end date changed from 17 Nov 2012 to 8 Dec 2012 as reported by European Clinical Trials Database record.
- 23 Jun 2012 Planned number of patients changed from 140 to 243 as reported by European Clinical Trials Database record.
- 23 Jun 2012 Additional location (Spain) added as reported by European Clinical Trials Database record.